CoChat

The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice

Open access
Gonzalez‐Ericsson, Paula I, Stovgaard, Elisabeth S, Sua, Luz F, Reisenbichler, Emily, Kos, Zuzana, Carter, Jodi M, Michiels, Stefan, Le Quesne, John, Nielsen, Torsten O, Lænkholm, Anne‐Vibeke, Fox, Stephen B, Adam, Julien, Bartlett, John MS, Rimm, David L, Quinn, Cecily, Peeters, Dieter, Dieci, Maria V, Vincent‐Salomon, Anne, Cree, Ian, Hida, Akira I, Balko, Justin M, Haynes, Harry R, Frahm, Isabel, Acosta‐Haab, Gabriela, Balancin, Marcelo, Bellolio, Enrique, Yang, Wentao, Kirtani, Pawan, Sugie, Tomoharu, Ehinger, Anna, Castaneda, Carlos A, Kok, Marleen, McArthur, Heather, Siziopikou, Kalliopi, Badve, Sunil, Fineberg, Susan, Gown, Allen, Viale, Giuseppe, Schnitt, Stuart J, Pruneri, Giancarlo, Penault‐Llorca, Frederique, Hewitt, Stephen, Thompson, E Aubrey, Allison, Kimberly H, Symmans, William F, Bellizzi, Andrew M, Brogi, Edi, Moore, David A, Larsimont, Denis, Dillon, Deborah A, Lazar, Alexander, Lien, Huangchun, Goetz, Matthew P, Broeckx, Glenn, El Bairi, Khalid, Harbeck, Nadia, Cimino‐Mathews, Ashley, Sotiriou, Christos, Adams, Sylvia, Liu, Shi‐wei, Loibl, Sibylle, Chen, I‐Chun, Lakhani, Sunil R, Juco, Jonathan W, Denkert, Carsten, Blackley, Elizabeth F, Demaria, Sandra, Leon‐Ferre, Roberto, Gluz, Oleg, Zardavas, Dimitrios, Emancipator, Kenneth, Ely, Scott, Loi, Sherene, Salgado, Roberto, Sanders, Melinda, International Immuno‐Oncology Biomarker Working Group · 2020 · The Journal of Pathology
Cited by 210

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitor therapies targeting PD‐1/PD‐L1 are now the standard of care in oncology across several hematologic and solid tumor types, including triple negative breast cancer (TNBC). Patients with metastatic or locally advanced TNBC with PD‐L1 expression on immune cells occupying ≥1% of tumor area demonstrated survival benefit with the addition of atezolizumab to nab‐paclitaxel. However, concerns regarding variability between immunohistochemical PD‐L1 assay performance and inter‐reader reproducibility have been raised. High tumor‐infiltrating lymphocytes (TILs) have also been associated with response to PD‐1/PD‐L1 inhibitors in patients with breast cancer (BC). TILs can be easily assessed on hematoxylin and eosin–stained slides and have shown reliable inter‐reader reproducibility. As an established prognostic factor in early stage TNBC, TILs are soon anticipated to be reported in daily practice in many pathology laboratories worldwide. Because TILs and PD‐L1 are parts of an immunological spectrum in BC, we propose the systematic implementation of combined PD‐L1 and TIL analyses as a more comprehensive immuno‐oncological biomarker for patient selection for PD‐1/PD‐L1 inhibition‐based therapy in patients with BC. Although practical and regulatory considerations differ by jurisdiction, the pathology community has the responsibility to patients to implement assays that lead to optimal patient selection. We propose herewith a risk‐management framework that may help mitigate the risks of suboptimal patient selection for immuno‐therapeutic approaches in clinical trials and daily practice based on combined TILs/PD‐L1 assessment in BC. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/path.5406

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 210

Metadata

Authors
Gonzalez‐Ericsson, P. I., Stovgaard, E. S., Sua, L. F., Reisenbichler, E., Kos, Z., Carter, J. M., Michiels, S., Le Quesne, J., Nielsen, T. O., Lænkholm, A., Fox, S. B., Adam, J., Bartlett, J. M., Rimm, D. L., Quinn, C., Peeters, D., Dieci, M. V., Vincent‐Salomon, A., Cree, I., Hida, A. I., Balko, J. M., Haynes, H. R., Frahm, I., Acosta‐Haab, G., Balancin, M., Bellolio, E., Yang, W., Kirtani, P., Sugie, T., Ehinger, A., Castaneda, C. A., Kok, M., McArthur, H., Siziopikou, K., Badve, S., Fineberg, S., Gown, A., Viale, G., Schnitt, S. J., Pruneri, G., Penault‐Llorca, F., Hewitt, S., Thompson, E. A., Allison, K. H., Symmans, W. F., Bellizzi, A. M., Brogi, E., Moore, D. A., Larsimont, D., Dillon, D. A., Lazar, A., Lien, H., Goetz, M. P., Broeckx, G., El Bairi, K., Harbeck, N., Cimino‐Mathews, A., Sotiriou, C., Adams, S., Liu, S., Loibl, S., Chen, I., Lakhani, S. R., Juco, J. W., Denkert, C., Blackley, E. F., Demaria, S., Leon‐Ferre, R., Gluz, O., Zardavas, D., Emancipator, K., Ely, S., Loi, S., Salgado, R., Sanders, M., & International Immuno‐Oncology Biomarker Working Group
Venue
The Journal of Pathology
Publisher
Wiley
Published
2020-04
Volume
250
Issue
5
Pages
667-684
ISSN
  • 0022-3417 (ISSN-L)
  • 1096-9896
OpenAlex
W3010122169
Cited by
210
References
10
FWCI
11.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.